Participants with known congestive heart failure (CHF); if known, patients with left ventricular ejection fraction (LVEF) =< % are excluded
History of myocardial infarction =<  months, current symptomatic CHF or left ventricular ejection fraction (LVEF) < % or > grade  diastolic dysfunction, with no symptoms or signs of heart failure
Left ventricular ejection fraction (LVEF) ?%. A lower LVEF (?%) is permissible if a formal cardiologic evaluation reveals no evidence for clinically significant functional impairment, otherwise the subject may not enter the study.
Left ventricular ejection fraction (LVEF) < %
Participants must have a left ventricular ejection fraction (LVEF) >= %
Left ventricular ejection fraction (LVEF) >= %
Left ventricular ejection fraction (LVEF) >= %
Participants must have a left ventricular ejection fraction (LVEF) >= %
Left ventricular ejection fraction (LVEF) < %, regardless of whether there are symptoms of heart failure
Any patient known to have a left ventricular ejection fraction (LVEF) less than or equal to %
Systolic cardiac function will be assessed at screening if clinically indicated by history and physical; only patients with left ventricular ejection fraction (LVEF) >= % will be eligible for enrollment
Any patient known to have an left ventricular ejection fraction (LVEF) less than or equal to %
Left ventricular ejection fraction (LVEF) within normal institutional limits
Left ventricular ejection fraction (LVEF) > %
Any patient known to have a left ventricular ejection fraction (LVEF) less than or equal to %
Patients who have a left ventricular ejection fraction (LVEF) < % at screening.
Left Ventricular Ejection Fraction (LVEF) >/=% HER-Expressing Breast Cancer-Specific Inclusion Criteria
Left ventricular ejection fraction (LVEF) >= %;
Any patient known to have an left ventricular ejection fraction (LVEF) =<  percent (%)
Uncontrolled cardiac disease, or myocardial infarction within the last  months, or left ventricular ejection fraction (LVEF) < %, or QTcF interval >  msec
Left ventricular ejection fraction (LVEF) >= %
Left ventricular ejection fraction (LVEF) >= ULN (institutional limit)
Left ventricular ejection fraction (LVEF) of >= %
Left ventricular ejection fraction (LVEF) >= %
Have left ventricular ejection fraction (LVEF) ?% assessed within  days prior to enrollment.
Left ventricular ejection fraction (LVEF) >= %
History of congestive heart failure and/or an left ventricular ejection fraction (LVEF) < %
Left ventricular ejection fraction (LVEF) >= %
Left ventricular ejection fraction (LVEF) of >= %
Left ventricular ejection fraction (LVEF) greater than or equal to (>/=)  percent (%)
Left ventricular ejection fraction (LVEF) <% at screening.
Patients with left ventricular ejection fraction (LVEF) < %
Left ventricular ejection fraction (LVEF) > %
Left ventricular ejection fraction (LVEF) ? %
Left ventricular ejection fraction (LVEF) >= %
Adequate cardiac function with left ventricular ejection fraction (LVEF) ? % at baseline.
Left ventricular ejection fraction (LVEF) below % or lifetime exposure to anthracyclines over mg/m of daunorubicin equivalent
Patients must have normal cardiac ejection fraction (left ventricular ejection fraction [LVEF] greater than or equal to %)
Patients must have normal cardiac ejection fraction (left ventricular ejection fraction [LVEF] >/= %)
Left ventricular ejection fraction (LVEF) ? %
Subjects must have a left ventricular ejection fraction (LVEF) of >= %
Left ventricular ejection fraction (LVEF) >= %; LVEF assessment must have been performed within  weeks of enrollment
Adequate cardiac function as evidenced by left ventricular ejection fraction (LVEF) greater than or equal to %) at baseline as determined by echocardiography.
Left ventricular ejection fraction (LVEF) > %
Left ventricular ejection fraction (LVEF) >= %
Left Ventricular Ejection Fraction (LVEF) ? %.
Baseline left ventricular ejection fraction (LVEF) >= %
Cardiac left ventricular ejection fraction (LVEF) > %
Left ventricular end diastolic function (LVEF) of >= %
Any patient known to have left ventricular ejection fraction (LVEF) =< %
Left ventricular end diastolic function (LVEF) of >= %
Left ventricular ejection fraction (LVEF) of >= %
Left ventricle ejection fraction (LVEF) >= %
Left ventricular ejection fraction (LVEF) >= %
Left ventricular ejection fraction (LVEF) <%
Adequate cardiac function defined by a left ventricular ejection fraction (LVEF) ?%, QTc < msec, and no evidence of clinically significant dysrhythmias on ECG
Left ventricular ejection fraction (LVEF) > %
Cardiac left ventricular ejection fraction (LVEF) > %
Patients must have a left ventricular ejection (LVEF) >= % within  days of enrollment
Measurement of left ventricular ejection fraction (LVEF) should be performed in patients with prior anthracycline exposure or known history of arrhythmia or structural heart disease; in these cases, LVEF must be >= %
Left ventricular ejection fraction (LVEF) > %
Left ventricular ejection fraction (LVEF) </=  percent (%) at screening
Left ventricular ejection fraction (LVEF) >= %
Cardiac insufficiency: left ventricular ejection fraction (LVEF) < % or coronary artery disease requiring treatment
Cardiac ejection fraction (left ventricular ejection fraction [LVEF]) >= %
Left ventricle ejection fraction (LVEF) >= %, specimens must be collected within  days prior to the start of study treatment
Left ventricular ejection fraction (LVEF) >= institutional normal
Baseline left ventricular ejection fraction (LVEF) >= %
Left ventricular ejection fraction (LVEF) =< %
Left ventricular ejection fraction (LVEF) >= % corrected
Contraindication to any drug in the chemotherapy regimen, and specifically: LVEF (Left Ventricular Ejection Fraction) < % or peripheral neuropathy grade 
Left ventricular ejection fraction (LVEF) < %;
Subject has a resting left ventricular ejection fraction (LVEF) of ? % obtained by echocardiography.
left ventricular ejection fraction (LVEF) of % or higher at baseline
Left ventricular ejection fraction (LVEF) >= %
Left ventricular ejection fraction (LVEF) > %
Left ventricular ejection fraction (LVEF) < %
Have LVEF (left ventricular ejection fraction) <% at screening
Left ventricular ejection fraction (LVEF) >= % (measured within  days of study entry)
Left ventricular ejection fraction (LVEF) ? %
Baseline left ventricular ejection fraction (LVEF) %.
Left ventricular ejection fraction (LVEF) >= %
A left ventricular ejection fraction (LVEF) must be > 
Cardiac: left ventricular ejection fraction (LVEF) at rest ? % (RIC cohort) or LVEF at rest ? % (FIC cohort), or left ventricular shortening fraction (LVFS) ? %
Left ventricular ejection fraction (LVEF) >= %
Left ventricular ejection fraction (LVEF) >= % for patients enrolling in the HER directed therapy arm
Left ventricular ejection fraction (LVEF) ?% assessed within  days prior to randomization.
Left ventricular ejection fraction (LVEF) ? % within the  days prior to randomization
Left ventricular ejection fraction (LVEF) >= % performed no more than  weeks prior to enrollment
If the left ventricular ejection fraction (LVEF) < , patients will be excluded
Left ventricular ejection fraction (LVEF) >= %
Left ventricular ejection fraction (LVEF) >= %
Left ventricular ejection fraction (LVEF) of >= %
Left ventricular ejection fraction (LVEF) >= % if patient has known cardiac dysfunction history
Left ventricular ejection fraction (LVEF) >= %
Subjects must have a left ventricular ejection fraction (LVEF) of >= %
Normal left ventricular ejection fraction (LVEF)
REGISTRATION INCLUSION CRITERIA: Adequate cardiac function as demonstrated by left ventricular ejection fraction (LVEF) of > % performed no more than  weeks prior to randomization
Baseline left ventricular ejection fraction (LVEF) value less than (<)  percent (%)
Resting left ventricular ejection fraction (LVEF) >= %
Left ventricular ejection fraction (LVEF) >= %
Patients must have a left ventricular ejection fraction (LVEF) of >= % AND/OR
Left ventricular ejection fraction (LVEF) >/= % within  days prior to first dose of study drug administration
The patient has an absence of coexisting medical problems that would significantly increase the risk of the chemotherapy procedure (e.g. poor left ventricular ejection fraction [LVEF<%])
Left ventricular ejection fraction (LVEF) >= %
History of documented congestive heart failure (CHF) or systolic dysfunction (left ventricular ejection fraction [LVEF] < %)
Left ventricular ejection fraction (LVEF) of > % by Doppler ultrasound assessment
Patient must have a normal left ventricular ejection fraction (LVEF) (>= %); if a patient has a borderline LVEF (-%) they may be considered after consultation with cardiology and study principal investigator (PI) and treated per the guidelines
Left ventricular ejection fraction (LVEF) >= %
Subjects > age  or with clinical signs of heart disease must have ejection fraction >= % left ventricular ejection fraction (LVEF) pre-transplant
Left ventricular ejection fraction (LVEF) >= %, however, subjects with a LVEF in the range of -% should have cardiology clearance prior to intervention
Left ventricular ejection fraction (LVEF) of >= %
Subjects who have a history of, or current evidence of uncontrolled cardiovascular disease or a left ventricular ejection fraction (LVEF) <%
Adequate left ventricular ejection fraction (LVEF) ? %
Left ventricular ejection fraction (LVEF) less than %
Cardiac left ventricular ejection fraction (LVEF) >= %
Known left ventricular ejection fraction (LVEF) < %
Left Ventricular Ejection Fraction (LVEF) ? % Part :
Left ventricular ejection fraction (LVEF) < %
Left ventricular ejection fraction (LVEF) >=  %
If the subject received prior anthracycline therapy, the left ventricular ejection fraction (LVEF) must be within institution's normal limits
LVEF (left ventricular ejection fraction) >= %
Patients with left ventricular ejection fraction (LVEF) < % will not be eligible
Left ventricular ejection fraction (LVEF) < %
Any patient known to have an left ventricular ejection fraction (LVEF) less than or equal to %
Any patient known to have a left ventricular ejection fraction (LVEF) less than or equal to %
Left ventricular ejection fraction (LVEF) ? %.
Left ventricular ejection fraction (LVEF) of at least %
Left ventricular ejection fraction (LVEF) >= %
Left ventricular ejection fraction (LVEF) >= %
Left ventricular ejection fraction (LVEF) >= %
Left ventricular ejection fraction (LVEF) >=  %
Left ventricular ejection fraction (LVEF) >= % (within  days)
Left ventricular ejection fraction (LVEF) >= %
If previously measured, left ventricular ejection fraction (LVEF) >= %
Left ventricular ejection fraction (LVEF) >= %
Left ventricular ejection fraction (LVEF) >= %
Left ventricular ejection fraction (LVEF) < %
Patients must have left ventricular ejection fraction (LVEF) > % or within institutional normal limits
Patients with a history of left ventricular (LV) dysfunction will be still candidates for enrollment in the study if they have documented left ventricular ejection fraction (LVEF) recovery (most recent documented LVEF of % or higher) for at least  months prior to SPECT regardless of current cardiac medication regimen
Left ventricular ejection fraction (LVEF) ? %
Significant cardiovascular disease including known left ventricular ejection fraction (LVEF) <%
